Strong demand for Glaxo's Trelegy Ellipta is likely to have driven royalties for Innoviva (INVA) in the first quarter.
Alkermes plc (Nasdaq: ALKS) today announced the presentation of new data from its schizophrenia portfolio as part of the virtual 2020 Congress of the Schizophrenia International Research Society (SIRS).
Alkermes plc (NASDAQ:ALKS) just released its first-quarter report and things are looking bullish. Revenues and losses...
Alkermes plc (Nasdaq: ALKS) announced today that management will participate in a fireside chat at the 2020 Bank of America Securities Virtual Health Care Conference on Wednesday, May 13, 2020 at 9:40 a.m. ET (2:40 p.m. BST). The webcast may be accessed under the Investors tab on www.alkermes.com and will be archived for 14 days.
Alkermes plc (Nasdaq: ALKS) today announced plans to present new research from its schizophrenia portfolio at the American Society of Clinical Psychopharmacology (ASCP) 2020 Annual Meeting, taking place virtually May 29-30, 2020.
The biotechnology industry is comprised of hundreds of companies that fuse biology and technology to develop drugs and related products for the treatment of diseases and medical conditions. Today's biotechnology industry includes companies that make medical devices and diagnostics, as well as biofuels, biomaterials, pollution controls, and more.
Alkermes plc (Nasdaq: ALKS) today reported financial results for the first quarter of 2020, and provided commentary related to the impact of the COVID-19 pandemic on the business.
Shares of Alkermes (NASDAQ:ALKS) rose 0.6% in pre-market trading after the company reported Q1 results.Quarterly Results Earnings per share increased 105.88% year over year to $0.01, which beat the estimate of ($0.06).Revenue of $246,220,000 up by 10.36% from the same period last year, which beat the estimate of $228,230,000.Looking Ahead Alkermes hasn't issued any earnings guidance for the time being.Alkermes hasn't issued any revenue guidance for the time being.Conference Call Details Date: Apr 29, 2020View more earnings on ALKSTime: 10:01 AM ETWebcast URL: https://edge.media-server.com/mmc/p/p7dhgcovRecent Stock Performance Company's 52-week high was at $31.00Company's 52-week low was at $11.98Price action over last quarter: down 9.40%Company Overview Alkermes PLC is a fully integrated global biotechnology company that applies its proprietary technologies to research, develop, and commercialize pharmaceutical products designed for unmet medical needs in major therapeutic areas. The company utilizes several collaborative arrangements to develop and commercialize products and, in so doing, to access technological, financial, marketing, manufacturing, and other resources. Alkermes either purchases active drug products from third parties or receives them from its third-party licensees to formulate products using its technologies.See more from Benzinga * 20 Healthcare Stocks Moving In Thursday's Pre-Market Session(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Alkermes plc (Nasdaq: ALKS) today announced the expansion of several programs and services in support of patient access to its proprietary medicines during the COVID-19 crisis. During this unprecedented and rapidly evolving situation, the company remains focused on helping to assure that patients have uninterrupted access to ARISTADA® (aripiprazole lauroxil), an injectable atypical antipsychotic for the treatment of schizophrenia in adults, and VIVITROL® (naltrexone for extended-release injectable suspension), indicated for the treatment of alcohol dependence and the prevention of relapse to opioid dependence following opioid detoxification.
Q1 2020 Alkermes Plc Earnings Call
Alkermes (ALKS) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Alkermes plc (Nasdaq: ALKS) today announced the publication of preclinical data demonstrating the selectivity and anti-tumor efficacy of its investigational, immunotherapy candidate, ALKS 4230, in the Journal for ImmunoTherapy of Cancer (JITC). ALKS 4230, a novel cytokine, is an investigational, engineered fusion protein designed to selectively expand tumor-killing immune cells while avoiding the interleukin-2 (IL-2)-induced activation of immunosuppressive cells by preferentially binding to the intermediate-affinity IL-2 receptor complex.
Alkermes (ALKS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ANIK vs. ALKS: Which Stock Is the Better Value Option?
We hate to say this but, we told you so. On February 27th we published an article with the title Recession is Imminent: We Need A Travel Ban NOW and predicted a US recession when the S&P 500 Index was trading at the 3150 level. We also told you to short the market and buy […]
Alkermes (ALKS) beats earnings and sales estimates for the first quarter of 2020. The company withdraws its previously provided outlook for 2020 amid uncertainty related to coronavirus.
ALKS earnings call for the period ending March 31, 2020.
Alkermes plc (Nasdaq: ALKS) today announced that data from its phase 3b ALPINE (Aripiprazole Lauroxil and Paliperidone palmitate: INitiation Effectiveness) study were published in the Journal of Clinical Psychiatry. ALPINE was a six-month study evaluating the efficacy and safety of the ARISTADA INITIO® (aripiprazole lauroxil) one-day initiation regimen, consisting of ARISTADA INITIO and one single dose of 30 mg of oral aripiprazole, together with the ARISTADA® (aripiprazole lauroxil) two-month dose in patients experiencing an acute exacerbation of schizophrenia. Positive topline data were first reported in April 2019. Results from the study provide evidence to support the use of the ARISTADA INITIO one-day regimen together with ARISTADA for treatment of an acute exacerbation of schizophrenia, started in the hospital setting and continued through the critical transition to outpatient care.
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it seems the smart money knows that...
Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET (1:00 p.m. BST) on Wednesday, April 29, 2020 to discuss the company's first quarter 2020 financial results. Management will also provide an update on the company.